E!4408, COZY01, CombiGene AB

Purpose and goal

We are developing COZY01, an innovative peptide-based therapy aimed at revolutionizing the treatment of chronic pain conditions. The uniqueness of COZY01 is its novel mechanism of action (MOA) that targets pain relief without the adverse and addictive side effects commonly associated with existing pain medications. The ultimate goal is to develop COZY01, a novel pain treatment that is a significantly safer and more effective alternative to opioids.

Expected effects and result

The main outcome of this project is that we will be able to commence with a First-in-Human (FiH) Clinical Study. This will be made possible by obtaining the following project results: 1) development and testing of a COZY01 formulation demonstrating favourable pharmacokinetic properties and analgesic effects in preclinical studies, 2) production of a COZY01 GMP drug product for the FiH Study, and 3) development of a comprehensive protocol for the FiH Study.

Planned approach and implementation

CombiGene and Zyneyro will work synergistically to complete the preclinical phase of COZY01 development and obtain a COZY01 GMP drug product ready for a FiH Study. CombiGene will be responsible for project management and development of the GMP product whilst Zyneyro will conduct experimental work focused on confirming effect of COZY01 in human tissue and preclinical testing of COZY01 formulations. The project has been divided into 4 work packages and will be implemented during 19 months.